Affymax, Inc. and Takeda Global Research & Development Center, Inc. to Present HematideTM/peginesatide Phase 2 Data at the National Kidney Foundation 2010 Spring Meeting

Published: Mar 30, 2010

PALO ALTO, Calif., & DEERFIELD, Ill.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY) and Takeda Pharmaceuticals Global Research & Development Center, Inc., U.S., today announced multiple posters on Hematideā„¢/peginesatide have been accepted for presentation at the National Kidney Foundation (NKF) 2010 Spring Clinical Meeting taking place April 13-17, 2010 in Orlando, Florida. Hematide is an investigational agent for the treatment of anemia in chronic renal failure (also referred to as renal anemia).

Back to news